JP2019533989A5 - 抗pd−1抗体及びその使用 - Google Patents
抗pd−1抗体及びその使用 Download PDFInfo
- Publication number
- JP2019533989A5 JP2019533989A5 JP2019512990A JP2019512990A JP2019533989A5 JP 2019533989 A5 JP2019533989 A5 JP 2019533989A5 JP 2019512990 A JP2019512990 A JP 2019512990A JP 2019512990 A JP2019512990 A JP 2019512990A JP 2019533989 A5 JP2019533989 A5 JP 2019533989A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human
- antibody
- cdr
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 title claims 23
- 108090001123 antibodies Proteins 0.000 title claims 23
- 102100013504 RPL17 Human genes 0.000 claims 21
- 108060007796 SPATA2 Proteins 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000004851 Immunoglobulin G Human genes 0.000 claims 4
- 230000000875 corresponding Effects 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 210000000987 Immune System Anatomy 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (23)
- (i)3つのCDRを含むVH鎖;及び(ii)3つのCDRを含むVL鎖を含む抗ヒトPD−1抗体であって、
VHCDR#1は、GYTFTHYGMN(配列番号11)であり、
VHCDR#2は、WVNTYTGEPTYADDFKG(配列番号12)であり、
VHCDR#3は、EGEGLGFGD(配列番号13)であり、
VLCDR#1は、RSSQSIVHSHGDTYLE(配列番号14)であり、
VLCDR#2は、KVSNRFS(配列番号15)であり、
VLCDR#3は、FQGSHIPVT(配列番号16)である、抗ヒトPD−1抗体。 - ヒト化されている、請求項1に記載の抗ヒトPD−1抗体。
- 配列番号36の配列に対応するVH鎖;及び配列番号42の配列に対応するVL鎖を含む、請求項1又は2に記載の抗ヒトPD−1抗体。
- IgGである、請求項1から3のいずれか一項に記載の抗ヒトPD−1抗体。
- IgG1である、請求項1から4のいずれか一項に記載の抗ヒトPD−1抗体。
- アミノ酸置換L234A及びL235Aを有する変異体CH2ドメインを含む、請求項5に記載の抗ヒトPD−1抗体。
- IgG4である、請求項4に記載の抗ヒトPD−1抗体。
- アミノ酸置換S228Pを有する変異体Fc領域を含む、請求項7に記載の抗ヒトPD−1抗体。
- カッパ軽定常領域を含む、請求項1から8のいずれか一項に記載の抗ヒトPD−1抗体。
- 配列番号51又は配列番号52の配列に対応する重鎖、及び配列番号61の配列に対応する軽鎖を含む、請求項3に記載の抗ヒトPD−1抗体。
- 配列番号51のアミノ酸配列からそれぞれなる重鎖及び配列番号61のアミノ酸配列からそれぞれなる軽鎖からなるIgG抗体である、請求項1に記載の抗ヒトPD−1抗体。
- 配列番号52のアミノ酸配列からそれぞれなる重鎖及び配列番号61のアミノ酸配列からそれぞれなる軽鎖からなるIgG抗体である、請求項1に記載の抗ヒトPD−1抗体。
- 請求項1から12のいずれか一項に記載の抗ヒトPD−1抗体及び薬学的に許容される担体を含む医薬組成物。
- 抗ヒトPD−1抗体をコードするヌクレオチド配列を含む核酸であって、抗体は、(i)3つのCDRを含むVH鎖;及び(ii)3つのCDRを含むVL鎖を含み、ここで
VHCDR#1は、GYTFTHYGMN(配列番号11)であり、
VHCDR#2は、WVNTYTGEPTYADDFKG(配列番号12)であり、
VHCDR#3は、EGEGLGFGD(配列番号13)であり、
VLCDR#1は、RSSQSIVHSHGDTYLE(配列番号14)であり、
VLCDR#2は、KVSNRFS(配列番号15)であり、
VLCDR#3は、FQGSHIPVT(配列番号16)である、核酸。 - 請求項14に記載の核酸を含むベクター。
- 請求項15に記載のベクターで形質転換された真核宿主細胞。
- 請求項14に記載の核酸を発現するように遺伝子操作された真核宿主細胞。
- 哺乳動物宿主細胞である、請求項16又は17に記載の真核宿主細胞。
- 抗ヒトPD−1抗体を生成する方法であって、(a)請求項16から18のいずれか一項に記載の宿主細胞を培養すること及び(b)抗ヒトPD−1抗体を回収することを含む、方法。
- 免疫系を活性化する必要のある患者の、免疫系の活性化に使用するための、請求項1から12のいずれか一項に記載の抗ヒトPD−1抗体。
- がんを治療する必要のある患者において、がんの治療に使用するための、請求項1から12のいずれか一項に記載の抗ヒトPD−1抗体。
- がんが、膀胱がん、乳がん、頭頸部がん、腎臓がん、肺がん、リンパ腫、黒色腫又は胃がんから選択される、請求項21に記載の使用のための抗ヒトPD−1抗体。
- 肺がんが、非小細胞肺がんである、請求項22に記載の使用のための抗ヒトPD−1抗体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662394314P | 2016-09-14 | 2016-09-14 | |
US62/394,314 | 2016-09-14 | ||
PCT/US2017/051531 WO2018053106A1 (en) | 2016-09-14 | 2017-09-14 | Anti-pd-1(cd279) antibodies |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019533989A JP2019533989A (ja) | 2019-11-28 |
JP2019533989A5 true JP2019533989A5 (ja) | 2020-11-12 |
JP7079773B2 JP7079773B2 (ja) | 2022-06-02 |
Family
ID=59955732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019512990A Active JP7079773B2 (ja) | 2016-09-14 | 2017-09-14 | 抗pd-1抗体及びその使用 |
Country Status (33)
Country | Link |
---|---|
US (4) | US9914783B1 (ja) |
EP (2) | EP3778643A1 (ja) |
JP (1) | JP7079773B2 (ja) |
KR (2) | KR102561356B1 (ja) |
CN (1) | CN109789205B (ja) |
AU (1) | AU2017326329B2 (ja) |
BR (1) | BR112019004998A2 (ja) |
CA (1) | CA3035932A1 (ja) |
CL (2) | CL2019000628A1 (ja) |
CO (1) | CO2019003154A2 (ja) |
CR (1) | CR20190199A (ja) |
CY (1) | CY1123642T1 (ja) |
DK (1) | DK3512547T3 (ja) |
DO (1) | DOP2019000056A (ja) |
EC (1) | ECSP19026178A (ja) |
ES (1) | ES2837755T3 (ja) |
HR (1) | HRP20201993T1 (ja) |
HU (1) | HUE051700T2 (ja) |
IL (2) | IL306104A (ja) |
LT (1) | LT3512547T (ja) |
MX (1) | MX2019002946A (ja) |
MY (1) | MY192158A (ja) |
PE (1) | PE20191102A1 (ja) |
PH (1) | PH12019500540A1 (ja) |
PL (1) | PL3512547T3 (ja) |
PT (1) | PT3512547T (ja) |
RS (1) | RS61204B1 (ja) |
RU (1) | RU2752562C2 (ja) |
SG (1) | SG10201914120XA (ja) |
SI (1) | SI3512547T1 (ja) |
UA (1) | UA124631C2 (ja) |
WO (1) | WO2018053106A1 (ja) |
ZA (1) | ZA201902265B (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA42447A (fr) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation |
CN116059218A (zh) | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
BR112018008867A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e seus usos |
KR102194188B1 (ko) | 2015-11-18 | 2020-12-24 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
EP3778643A1 (en) * | 2016-09-14 | 2021-02-17 | AbbVie Biotherapeutics Inc. | Pharmaceutical uses of anti-pd-1(cd279) antibodies |
RS65448B1 (sr) | 2016-10-26 | 2024-05-31 | Iovance Biotherapeutics Inc | Restimulacija krioprezerviranih tumor-infiltrirajućih limfocita |
JP7275030B2 (ja) | 2017-01-20 | 2023-05-17 | タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド | 抗pd-1抗体およびその使用 |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
EP3635097A1 (en) | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
BR112019025574A2 (pt) | 2017-06-05 | 2020-06-23 | Janssen Biotech, Inc. | Anticorpos que se ligam especificamente ao pd-1 e métodos de uso |
US11690920B2 (en) | 2017-07-13 | 2023-07-04 | Northwestern University | General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles |
US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
AU2019257749A1 (en) | 2018-04-27 | 2020-10-22 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2020018413A1 (en) | 2018-07-15 | 2020-01-23 | Enochian BioPharma, Inc. | Methods and compositions using recombinant dendritic cells for cancer therapy |
CN112424231B (zh) * | 2018-07-19 | 2022-09-13 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其剂量和用途 |
AU2019409805A1 (en) | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional anti-PD-1/SIRPA molecule |
BR112021011982A2 (pt) | 2018-12-21 | 2021-09-14 | Ose Immunotherapeutics | Anticorpo anti-humano-pd-1 humanizado |
CA3122899A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
JP2022514702A (ja) | 2018-12-21 | 2022-02-14 | オーエスイー・イミュノセラピューティクス | 二機能性抗pd-1/il-7分子 |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
PL3927347T3 (pl) * | 2019-02-18 | 2024-05-06 | Medivir Aktiebolag | Kombinacja leków do stosowania w sposobie leczenia raka wątroby |
EP3931349A4 (en) * | 2019-02-28 | 2023-02-08 | The Rockefeller University | APOE GENOTYPING IN CANCER PROGNOSTIC AND TREATMENT |
AU2020281535A1 (en) | 2019-05-24 | 2022-01-27 | Merck Patent Gmbh | Combination therapies using CDK inhibitors |
EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | 包含il-7變體之雙官能分子 |
WO2021158884A1 (en) * | 2020-02-07 | 2021-08-12 | Bioxcel Therapeutics, Inc. | Treatment regimen for cancer using immunomodulation |
KR20230060531A (ko) * | 2020-08-31 | 2023-05-04 | 바이오션, 인코포레이티드 | Pd-1에 결합하는 항체 및 이의 용도 |
WO2022101358A1 (en) * | 2020-11-11 | 2022-05-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
CA3201729A1 (en) | 2020-12-17 | 2022-06-23 | Nicolas Poirier | Bifunctional anti-pd1/il-7 molecules |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
US20240182571A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
AU2023212994A1 (en) * | 2022-01-28 | 2024-08-08 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
US20240150487A1 (en) * | 2022-03-04 | 2024-05-09 | Trishula Therapeutics Inc. | Combinations with an anti human cd39 antibody, an anti human pd-1 antibody, and chemotherapy in gastric cancer |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
KR100654645B1 (ko) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
CA2286879C (en) | 1997-04-14 | 2003-12-16 | Peter Kufer | Novel method for the production of anti-human antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP1135498B1 (en) | 1998-11-18 | 2008-01-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
PL362804A1 (en) | 1999-08-23 | 2004-11-02 | Dana-Farber Cancer Institute | Novel b7-4 molecules and uses therefor |
AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
MXPA03008959A (es) | 2001-04-02 | 2004-10-15 | Wyeth Corp | Pd-1, un receptor para b7-4 y sus usos. |
WO2003006636A1 (de) | 2001-07-12 | 2003-01-23 | Genethor Gmbh | Reduktion der stimulationsfähigkeit von antigen präsentierenden zellen |
WO2003011911A1 (en) | 2001-07-31 | 2003-02-13 | Ono Pharmaceutical Co., Ltd. | Substance specific to pd-1 |
EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
JP4532409B2 (ja) | 2003-01-23 | 2010-08-25 | 小野薬品工業株式会社 | ヒトpd−1に対し特異性を有する物質 |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
NZ561211A (en) | 2005-03-25 | 2011-03-31 | Genentech Inc | Methods and compositions for modulating hyperstabilized C-met |
EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CA3045637A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
US20080292625A1 (en) * | 2007-04-18 | 2008-11-27 | Sally Schroeter | Prevention and treatment of cerebral amyloid angiopathy |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
PE20110435A1 (es) * | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
JP6087503B2 (ja) | 2008-09-26 | 2017-03-08 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ヒト抗pd−1、pd−l1、及びpd−l2抗体とその用途 |
WO2014093786A1 (en) * | 2012-12-14 | 2014-06-19 | Abbvie, Inc. | Methods for increasing the efficiency of hybridoma generation |
SI2935331T1 (en) | 2012-12-24 | 2018-06-29 | Abbvie Inc. | Protein that binds the prolactin receptor and its use |
WO2014144960A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotherapeutics Inc. | Fc variants |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
US9493568B2 (en) | 2014-03-21 | 2016-11-15 | Abbvie Inc. | Anti-EGFR antibodies and antibody drug conjugates |
SG11201609468WA (en) | 2014-05-29 | 2016-12-29 | Medimmune Ltd | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
CA2966005C (en) | 2014-10-31 | 2021-04-27 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
WO2016073845A1 (en) * | 2014-11-07 | 2016-05-12 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
EP3237446B1 (en) * | 2014-12-22 | 2021-05-05 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
JP2019500327A (ja) | 2015-11-30 | 2019-01-10 | アッヴィ・インコーポレイテッド | 抗huLRRC15抗体薬物コンジュゲート及びその使用方法 |
AU2016365117A1 (en) | 2015-11-30 | 2018-05-31 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
MX2018011425A (es) | 2016-03-21 | 2019-09-04 | B Weiner David | Construcciones de anticuerpos de adn y método para utilizarlas. |
EP3778643A1 (en) * | 2016-09-14 | 2021-02-17 | AbbVie Biotherapeutics Inc. | Pharmaceutical uses of anti-pd-1(cd279) antibodies |
-
2017
- 2017-09-14 EP EP20196903.7A patent/EP3778643A1/en not_active Withdrawn
- 2017-09-14 RS RS20201518A patent/RS61204B1/sr unknown
- 2017-09-14 SI SI201730531T patent/SI3512547T1/sl unknown
- 2017-09-14 CN CN201780055621.1A patent/CN109789205B/zh active Active
- 2017-09-14 EP EP17772258.4A patent/EP3512547B1/en active Active
- 2017-09-14 US US15/704,296 patent/US9914783B1/en active Active
- 2017-09-14 SG SG10201914120XA patent/SG10201914120XA/en unknown
- 2017-09-14 UA UAA201903714A patent/UA124631C2/uk unknown
- 2017-09-14 PL PL17772258T patent/PL3512547T3/pl unknown
- 2017-09-14 AU AU2017326329A patent/AU2017326329B2/en active Active
- 2017-09-14 MX MX2019002946A patent/MX2019002946A/es unknown
- 2017-09-14 BR BR112019004998A patent/BR112019004998A2/pt unknown
- 2017-09-14 RU RU2019110835A patent/RU2752562C2/ru active
- 2017-09-14 CA CA3035932A patent/CA3035932A1/en active Pending
- 2017-09-14 KR KR1020197010300A patent/KR102561356B1/ko active IP Right Grant
- 2017-09-14 IL IL306104A patent/IL306104A/en unknown
- 2017-09-14 IL IL265179A patent/IL265179B2/en unknown
- 2017-09-14 HU HUE17772258A patent/HUE051700T2/hu unknown
- 2017-09-14 CR CR20190199A patent/CR20190199A/es unknown
- 2017-09-14 LT LTEP17772258.4T patent/LT3512547T/lt unknown
- 2017-09-14 KR KR1020237025514A patent/KR20230114331A/ko active Application Filing
- 2017-09-14 DK DK17772258.4T patent/DK3512547T3/da active
- 2017-09-14 MY MYPI2019001212A patent/MY192158A/en unknown
- 2017-09-14 JP JP2019512990A patent/JP7079773B2/ja active Active
- 2017-09-14 WO PCT/US2017/051531 patent/WO2018053106A1/en unknown
- 2017-09-14 PE PE2019000521A patent/PE20191102A1/es unknown
- 2017-09-14 PT PT177722584T patent/PT3512547T/pt unknown
- 2017-09-14 ES ES17772258T patent/ES2837755T3/es active Active
-
2018
- 2018-01-19 US US15/875,970 patent/US20180148513A1/en not_active Abandoned
-
2019
- 2019-03-11 DO DO2019000056A patent/DOP2019000056A/es unknown
- 2019-03-12 CL CL2019000628A patent/CL2019000628A1/es unknown
- 2019-03-13 PH PH12019500540A patent/PH12019500540A1/en unknown
- 2019-03-29 CO CONC2019/0003154A patent/CO2019003154A2/es unknown
- 2019-04-10 ZA ZA2019/02265A patent/ZA201902265B/en unknown
- 2019-04-12 EC ECSENADI201926178A patent/ECSP19026178A/es unknown
- 2019-10-22 US US16/660,634 patent/US10730953B2/en active Active
- 2019-12-11 CL CL2019003627A patent/CL2019003627A1/es unknown
-
2020
- 2020-06-22 US US16/907,794 patent/US20200317808A1/en not_active Abandoned
- 2020-12-09 CY CY20201101165T patent/CY1123642T1/el unknown
- 2020-12-14 HR HRP20201993TT patent/HRP20201993T1/hr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019533989A5 (ja) | 抗pd−1抗体及びその使用 | |
RU2019110835A (ru) | Антитела к pd-1(cd279) | |
JP2020504101A5 (ja) | ||
JP2019523221A5 (ja) | ||
IL268620B1 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
JP2019500893A5 (ja) | ||
JP2020532965A5 (ja) | ||
JP2018527919A5 (ja) | ||
JP2019500891A5 (ja) | ||
JP2018035138A5 (ja) | ||
JP2020531048A5 (ja) | ||
JP2019527047A5 (ja) | ||
JP2012530496A5 (ja) | ||
JP2019500892A5 (ja) | ||
RU2018146533A (ru) | Антитела к cd40 и пути их применения | |
JP2018527952A5 (ja) | ||
RU2019121895A (ru) | Анти-ох40 антитела и их применение | |
RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
FI3283524T3 (fi) | Bispesifisiä vasta-ainekonstrukteja cdh3:lle ja cd3:lle | |
JP2016514463A5 (ja) | ||
RU2016138422A (ru) | Химерный антигенный рецептор | |
JP2018522541A5 (ja) | ||
JP2011518546A5 (ja) | ||
JP2020505386A5 (ja) | ||
JP2013520984A5 (ja) |